Evidence map›Paper›PMID 24401642›Full record

ReviewAIDS (London, England)2014

Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges.

Paul G Rubinstein, David M Aboulafia, Andrew Zloza

Registry-linked trialAbstract readEditorialReview
PubMed Full text at PMC Publisher
In one paragraph

Review in AIDS (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04735445 (IMPACt of an Enhanced Screening Program on the Detection of Non-AIDS NEOplasms in Patients With Human Immunodeficiency Virus), which is not on this map. Cited by 108 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 6 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04735445 naunknown statusnot on this mapstarted 2019, after this paper: background citation

IMPACt of an Enhanced Screening Program on the Detection of Non-AIDS NEOplasms in Patients With Human Immunodeficiency Virus (HIV) Infection

TypeinterventionalSponsorFelix GutierrezRan2019 to 2023Enrolled4,638ConditionsHIV/AIDS, CancerArmsDigital rectal exam and / or anal cytology (day 1 and after 36 months), Semestral digital rectal exam and / or anal cytology if abnormal → ANOSCOPY with biopsy, Cervical cytology and cervical sample for HPV detection (day 1 and after 36 months), Semestral cervical cytology and cervical sample for HPV detection, Appointment for mammography (day 1 and after 36 months)
3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 6 syntheses or guidelines pooled it, 233 citations in OpenAlex.

  1. Pooled it
  2. Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2015
    Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Observational
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Paul G RubinsteinaSection of Hematology/Oncology, Department of Medicine, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research bDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois cDivision of Hematology and Oncology, Virginia Mason Medical Center, and the Division of Hematology, University of Washington, Seattle, Washington dDepartment of Immunology/Microbiology, Rush University Cancer Center, Developmental Center for AIDS Research, Rush University Medical Center, Chicago, Illinois, USA. *Paul G. Rubinstein and David M. Aboulafia contributed equally to the writing of this article.
David M Aboulafia
Andrew Zloza
Rush University Medical Center · USRuth M. Rothstein CORE Center · USVirginia Mason Medical Center · US

Funding

University of Southern CaliforniaU01CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KROWN, SUSAN E · 2006 to 2014
$54.7M
NCI NIH HHS U01 CA121947NCI NIH HHS U01CA121947
6 · The paper itself

Abstract

The incidence of AIDS-defining cancers (ADCs) - Kaposi sarcoma, primary central nervous system lymphoma, non-Hodgkin lymphoma, and cervical cancer - although on the decline since shortly after the introduction of HAART, has continued to be greater even in treated HIV-infected persons than in the general population. Although the survival of newly infected people living with HIV/AIDS now rivals that of the general population, morbidity and mortality associated with non-AIDS-defining cancers (NADCs) such as lung, liver, anal, and melanoma are significant and also continue to rise. Increasing age (i.e. longevity) is the greatest risk factor for NADCs, but longevity alone is not sufficient to fully explain these trends in cancer epidemiology. In this review, we briefly review the epidemiology and etiology of cancers seen in HIV/AIDS, and in this context, discuss preclinical research and broad treatment considerations. Investigation of these considerations provides insight into why malignancies continue to be a major problem in the current era of HIV/AIDS care.

Indexed as

HIV InfectionsHumansIncidenceNeoplasms

Identifiers

PMID24401642
PMCPMC4501859
OpenAlexW2036550854

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.